Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MSB 0010445

Next Previous
Drug Profile

MSB 0010445

Alternative Names: EMD 521873; MSB0010445; NHS-IL2; NHS-IL2-LT; Selectikine

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EMD Serono; Merck Serono
  • Class Antineoplastics; Cytokines; Drug conjugates; Immunoconjugates; Recombinant fusion proteins
  • Mechanism of Action Interleukin-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 30 Nov 2013 Phase-II clinical trials in Malignant melanoma (second-line therapy or greater, late-stage disease) in USA (IV)
  • 25 Oct 2013 EMD Serono plans a phase IIa trial for Malignant melanoma (unresectable or metastatic disease) in USA (NCT01973608)
  • 31 Jan 2012 Merck completes a phase I trial in Non-Hodgkin's lymphoma and Solid tumours in Germany and Switzerland (NCT00879866)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top